111 related articles for article (PubMed ID: 3465673)
1. A study of the hypolipidemic effect of estrogen in type III hyperlipoproteinemia.
Stuyt PM; Demacker PN; van't Laar A
Horm Metab Res; 1986 Sep; 18(9):607-10. PubMed ID: 3465673
[TBL] [Abstract][Full Text] [Related]
2. Studies in asymptomatic primary hyperlipidaemia. IV. ECG at rest and during exercise and its relation to various lipoprotein classes.
Olsson AG; Ekelund LG; Carlson LA
Acta Med Scand; 1975; 198(1-2):55-73. PubMed ID: 170796
[TBL] [Abstract][Full Text] [Related]
3. Catabolism of very-low-density lipoproteins in subjects with broad beta disease: comparison with endogenous hypertriglyceridemia.
Kushwaha RS; Chait A; Hazzard WR
J Lab Clin Med; 1982 Jan; 99(1):15-24. PubMed ID: 6948063
[TBL] [Abstract][Full Text] [Related]
4. Simvastatin in the effective reduction of plasma lipoprotein levels in familial dysbetalipoproteinemia (type III hyperlipoproteinemia).
Stuyt PM; Mol MJ; Stalenhoef AF; Demacker PN; Van 't Laar A
Am J Med; 1990 Jan; 88(1N):42N-45N. PubMed ID: 2368763
[TBL] [Abstract][Full Text] [Related]
5. Comparative effects of bezafibrate and micronised fenofibrate in patients with type III hyperlipoproteinemia.
Feussner G; Kurth B; Lohrmann J
Eur J Med Res; 1997 Apr; 2(4):165-8. PubMed ID: 9110923
[TBL] [Abstract][Full Text] [Related]
6. Effects of estrogen therapy on apolipoprotein E in type II hyperlipoproteinemia.
Falko JM; Schonfeld G; Witztum JL; Kolar J; Weidman SW
Metabolism; 1979 Nov; 28(11):1171-7. PubMed ID: 226834
[No Abstract] [Full Text] [Related]
7. Metabolic effects of oral contraceptives containing 30 micrograms and 50 micrograms of oestrogen.
Nash AL; Cornish EJ; Hain R
Med J Aust; 1979 Sep; 2(6):277-81. PubMed ID: 230411
[TBL] [Abstract][Full Text] [Related]
8. Control of 3-hydroxy-3-methylglutaryl-CoA reductase activity in cultured human fibroblasts by very low density lipoproteins of subjects with hypertriglyceridemia.
Gianturco SH; Gotto AM; Jackson RL; Patsch JR; Sybers HD; Taunton OD; Yeshurun DL; Smith LC
J Clin Invest; 1978 Feb; 61(2):320-8. PubMed ID: 202612
[TBL] [Abstract][Full Text] [Related]
9. The effect of tibolone on the lipoprotein profile of postmenopausal women with type III hyperlipoproteinemia.
de Beer F; Smelt AH; van Vark LC; Hoogerbrugge N; Havekes LM; Gevers Leuven JA
J Intern Med; 2002 Feb; 251(2):148-55. PubMed ID: 11908467
[TBL] [Abstract][Full Text] [Related]
10. Oxandrolone and plasma triglyceride reduction: effect on triglyceride-rich and high density lipoproteins.
Hara T; Miller JP; Gotto AM; Patsch JR
Artery; 1981; 9(5):328-41. PubMed ID: 7316782
[TBL] [Abstract][Full Text] [Related]
11. Lowering effect of fenofibrate (procetofene) on lipoproteins in different types of hyperlipoproteinemias.
Canzler H; Bojanovski D
Artery; 1980; 8(2):171-8. PubMed ID: 7458684
[TBL] [Abstract][Full Text] [Related]
12. [Fenofibrate: hypolipaemic activity and safety in long-term treatment. Effects on HDL, LDL, VLDL and apoprotein B in short-term treatment (author's transl)].
Rouffy J; Sauvanet JP; Chanu B; Bakir R; Goy-Loeper J; Saya C; Pinaroli F
Nouv Presse Med; 1980 Dec; 9(49):3747-51. PubMed ID: 7208341
[TBL] [Abstract][Full Text] [Related]
13. Type III hyperlipoproteinemia: paradoxical hypolipidemic response to estrogen.
Kushwaha RS; Hazzard WR; Gagne C; Chait A; Albers JJ
Ann Intern Med; 1977 Nov; 87(5):517-25. PubMed ID: 200161
[TBL] [Abstract][Full Text] [Related]
14. Effects of a new fish oil concentrate on plasma lipids and lipoproteins in patients with hypertriglyceridaemia.
Mackness MI; Bhatnagar D; Durrington PN; Prais H; Haynes B; Morgan J; Borthwick L
Eur J Clin Nutr; 1994 Dec; 48(12):859-65. PubMed ID: 7889894
[TBL] [Abstract][Full Text] [Related]
15. The effects of colestipol on the metabolism of very-low-density lipoproteins in man.
Witztum JL; Schonfeld G; Weidman SW
J Lab Clin Med; 1976 Dec; 88(6):1008-18. PubMed ID: 186544
[TBL] [Abstract][Full Text] [Related]
16. Cholesterol in the plasma very low density lipoprotein fraction in patients with type III hyperlipoproteinemia: analysis of factors which modulate its concentration.
Sutherland WH; Janus ED; Nye ER; Grant S
Biochem Med Metab Biol; 1988 Jun; 39(3):305-11. PubMed ID: 3165001
[TBL] [Abstract][Full Text] [Related]
17. [Normalization of lipid levels in an 87-year-old woman with a type III dysbetalipoproteinemia by ethinyl estradiol (author's transl)].
De Gennes JL; Dairou F; Epelboin S; Tuffert J
Ann Med Interne (Paris); 1980; 131(7):410-5. PubMed ID: 7224448
[TBL] [Abstract][Full Text] [Related]
18. Preliminary report: treatment of type 3 hyperlipoproteinemia with mevinolin.
East CA; Grundy SM; Bilheimer DW
Metabolism; 1986 Feb; 35(2):97-8. PubMed ID: 3633017
[TBL] [Abstract][Full Text] [Related]
19. [The relationship of cholesterol (CHO) and triglycerides (TG) in VLDL, LDL, and VLDL subfractions by agarose gel electrophoresis, using CHO and TG dual staining (AG-CHO, TG staining)].
Miyake N; Iizuka K
Rinsho Byori; 2002 Jun; 50(6):605-12. PubMed ID: 12166081
[TBL] [Abstract][Full Text] [Related]
20. Gemfibrozil therapy in primary type II hyperlipoproteinemia: effects on lipids, lipoproteins and apolipoproteins.
Lupien PJ; Brun D; Gagné C; Moorjani S; Bielman P; Julien P
Can J Cardiol; 1991; 7(1):27-33. PubMed ID: 2025787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
